MX2024004552A - Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas. - Google Patents
Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas.Info
- Publication number
- MX2024004552A MX2024004552A MX2024004552A MX2024004552A MX2024004552A MX 2024004552 A MX2024004552 A MX 2024004552A MX 2024004552 A MX2024004552 A MX 2024004552A MX 2024004552 A MX2024004552 A MX 2024004552A MX 2024004552 A MX2024004552 A MX 2024004552A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrrolo
- dyrk1a
- inhibitors
- triazine compounds
- triazines derivatives
- Prior art date
Links
- KGRPHHFLPMPUBB-UHFFFAOYSA-N pyrrolo[2,1-f][1,2,4]triazine Chemical class C1=NC=NN2C=CC=C21 KGRPHHFLPMPUBB-UHFFFAOYSA-N 0.000 title abstract 3
- 101150086683 DYRK1A gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 abstract 1
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163254733P | 2021-10-12 | 2021-10-12 | |
| US202263347757P | 2022-06-01 | 2022-06-01 | |
| PCT/US2022/046416 WO2023064366A1 (en) | 2021-10-12 | 2022-10-12 | Pyrrolo[2,1-f][1,2,4]triazines derivatives as inhibitors of dyrk1a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004552A true MX2024004552A (es) | 2024-06-04 |
Family
ID=84330173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004552A MX2024004552A (es) | 2021-10-12 | 2022-10-12 | Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12134625B2 (enExample) |
| EP (1) | EP4415816B1 (enExample) |
| JP (1) | JP2024539620A (enExample) |
| KR (1) | KR20240089275A (enExample) |
| AU (1) | AU2022367222A1 (enExample) |
| CA (1) | CA3234831A1 (enExample) |
| IL (1) | IL312157A (enExample) |
| MX (1) | MX2024004552A (enExample) |
| PY (1) | PY2289204A (enExample) |
| TW (1) | TW202322800A (enExample) |
| UY (1) | UY39979A (enExample) |
| WO (1) | WO2023064366A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3249870A1 (en) * | 2022-01-25 | 2023-08-03 | Kinnate Biopharma Inc. | CDK4/6 KINASE INHIBITORS |
| EP4611890A1 (en) * | 2022-11-03 | 2025-09-10 | BioSplice Therapeutics, Inc. | 4-aminopyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof |
| WO2024211797A1 (en) * | 2023-04-07 | 2024-10-10 | Biosplice Therapeutics, Inc. | Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof |
| CN119019402A (zh) * | 2023-05-24 | 2024-11-26 | 中国科学院上海有机化学研究所 | 作为lrrk2激酶抑制剂的多环化合物及其制备方法和用途 |
| WO2025024707A1 (en) * | 2023-07-26 | 2025-01-30 | Kinnate Biopharma Inc. | Inhibitors of cdk2/4/6 kinase |
| US20250206746A1 (en) * | 2023-12-22 | 2025-06-26 | Biosplice Therapeutics, Inc. | 4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
| US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
| DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
| US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
| US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
| US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
| ES2364340T3 (es) | 2004-03-30 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | Azaindoles útiles como inhibidores de jak y otras proteína quinasas. |
| US20060264897A1 (en) | 2005-01-24 | 2006-11-23 | Neurosystec Corporation | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues |
| US20110201599A1 (en) | 2008-07-03 | 2011-08-18 | Exelixis, Inc. | CDK Modulators |
| WO2011018894A1 (en) | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| MX365640B (es) | 2012-12-21 | 2019-06-10 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas y sus indicaciones. |
| WO2016010886A1 (en) | 2014-07-14 | 2016-01-21 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| US10730842B2 (en) * | 2015-09-03 | 2020-08-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK1A and uses thereof |
| FR3041640B1 (fr) | 2015-09-30 | 2019-05-17 | Les Laboratoires Servier | NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT |
| RU2020115154A (ru) * | 2017-10-10 | 2021-11-15 | Сирос Фармасьютикалз, Инк. | Производные пирролотриазина и способы ингибирования киназ там |
| EP3759072A4 (en) | 2018-03-01 | 2021-11-03 | The Trustees of Columbia University in the City of New York | COMPOUNDS, COMPOSITIONS AND METHODS FOR RELATING TOXIC STRESS FROM ENDOPLASMIC RETICULUM |
| US12528810B2 (en) * | 2018-03-01 | 2026-01-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK/CLK and uses thereof |
| EP3813826A4 (en) | 2018-06-26 | 2022-07-06 | BioSplice Therapeutics, Inc. | METHOD OF TREATMENT OF CANCER USING A CLK INHIBITOR |
| WO2020081689A1 (en) | 2018-10-16 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Azaindole inhibitors of wild-type and mutant forms of lrrk2 |
| US20230000842A1 (en) | 2019-01-17 | 2023-01-05 | Samumed, Llc | Methods of treating cartilage disorders through inhibition of clk and dyrk |
| WO2021257863A1 (en) * | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| AU2021313150A1 (en) | 2020-07-20 | 2023-03-16 | Nido Biosciences, Inc. | Indole compounds as androgen receptor modulators |
| PY2289206A (es) | 2021-10-12 | 2023-11-09 | Biosplice Therapeutics Inc | 7h-pirrolo[2,3-d] pirimidinas y preparación y usos de las mismas |
| WO2023064349A1 (en) | 2021-10-12 | 2023-04-20 | Biosplice Therapeutics, Inc. | 1h-pyrrolo[2,3-b]pyridines as dyrk1a inhibitors |
| EP4543886A1 (en) | 2022-06-23 | 2025-04-30 | BioSplice Therapeutics, Inc. | 4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof |
-
2022
- 2022-10-12 CA CA3234831A patent/CA3234831A1/en active Pending
- 2022-10-12 US US17/964,489 patent/US12134625B2/en active Active
- 2022-10-12 AU AU2022367222A patent/AU2022367222A1/en active Pending
- 2022-10-12 MX MX2024004552A patent/MX2024004552A/es unknown
- 2022-10-12 JP JP2024522052A patent/JP2024539620A/ja active Pending
- 2022-10-12 PY PY202202289204A patent/PY2289204A/es unknown
- 2022-10-12 TW TW111138697A patent/TW202322800A/zh unknown
- 2022-10-12 KR KR1020247014718A patent/KR20240089275A/ko active Pending
- 2022-10-12 WO PCT/US2022/046416 patent/WO2023064366A1/en not_active Ceased
- 2022-10-12 UY UY0001039979A patent/UY39979A/es unknown
- 2022-10-12 EP EP22801289.4A patent/EP4415816B1/en active Active
- 2022-10-12 IL IL312157A patent/IL312157A/en unknown
-
2024
- 2024-08-15 US US18/806,231 patent/US20250171466A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230312605A1 (en) | 2023-10-05 |
| PY2289204A (es) | 2023-12-05 |
| US12134625B2 (en) | 2024-11-05 |
| KR20240089275A (ko) | 2024-06-20 |
| TW202322800A (zh) | 2023-06-16 |
| IL312157A (en) | 2024-06-01 |
| JP2024539620A (ja) | 2024-10-29 |
| EP4415816B1 (en) | 2026-03-18 |
| US20250171466A1 (en) | 2025-05-29 |
| UY39979A (es) | 2023-04-14 |
| AU2022367222A1 (en) | 2024-05-02 |
| EP4415816A1 (en) | 2024-08-21 |
| CA3234831A1 (en) | 2023-04-20 |
| WO2023064366A1 (en) | 2023-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024004552A (es) | Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas. | |
| MX2024015663A (es) | 4-alcoxipirrolo[2,1-f][1,2,4]triazinas y preparación y uso de las mismas | |
| GEP20237561B (en) | Protein tyrosine phosphatase inhibitors | |
| MX2022005399A (es) | Compuestos. | |
| ZA202209894B (en) | Compounds for targeted degradation of brd9 | |
| PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| MX2023007218A (es) | Cocristal de un inhibidor de cinasa dependiente de ciclina (cdk). | |
| PH12020550881A1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| MX2021015262A (es) | Inhibidores de prmt5. | |
| MY132789A (en) | Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals | |
| MY200590A (en) | Compounds useful as kinase inhibitors | |
| MY144483A (en) | 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases | |
| MX2009000333A (es) | Pirrilopirimidinas para composiciones farmaceuticas. | |
| IL159843A0 (en) | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| GEP20084439B (en) | Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof | |
| MX2024013838A (es) | Compuestos y usos de estos | |
| MXPA03011083A (es) | Compuestos de sulfonamida sustituida, procedimiento para su preparacion, y su uso como medicamento para el tratamiento de trastornos del sistema nervioso central. obesidad y diabetes tipo ii. | |
| BR112023002089A2 (pt) | Compostos de piridazina 6-substituídos como degradadores de smarca2 e/ou smarca4 | |
| MX2020008816A (es) | Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas. | |
| CR20240101A (es) | COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-y (DIVISIONAL 2020-464) | |
| PH12020551300A1 (en) | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| MX2025007502A (es) | Inhibidor de la proteina tirosina quinasa y su uso farmaceutico | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. |